Company
Immuneering Corp (IMRX)
Standardized SEC financial data for Immuneering Corp — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001790340 · NASDAQ · Pharmaceutical Preparations.
Revenue growth (YoY)
-100.0%
Return on equity
-25.6%
Free cash flow
-$45.5M
Current ratio
17.50×
EPS (diluted)
$-1.27
Ratios for fiscal year 2023, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $2.1M | $317K | $0 | — | — |
| Cost of revenue |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $37.1M | $74.9M | $72.6M | $59.4M | $36.1M | $128.6M |
| Total current assets |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$14.6M | -$30.9M | -$44.1M | -$49.0M | -$55.0M | -$45.3M |
| Capital expenditures |
Get IMRX data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/IMRX/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/IMRX/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"